Cargando…

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma

Detalles Bibliográficos
Autor principal: Hallam, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745997/
https://www.ncbi.nlm.nih.gov/pubmed/31723786
http://dx.doi.org/10.1097/HS9.0000000000000137
_version_ 1783451635682377728
author Hallam, Simon
author_facet Hallam, Simon
author_sort Hallam, Simon
collection PubMed
description
format Online
Article
Text
id pubmed-6745997
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67459972019-11-13 Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma Hallam, Simon Hemasphere HemaTopics Wolters Kluwer Health 2018-07-26 /pmc/articles/PMC6745997/ /pubmed/31723786 http://dx.doi.org/10.1097/HS9.0000000000000137 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle HemaTopics
Hallam, Simon
Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
title Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
title_full Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
title_fullStr Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
title_full_unstemmed Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
title_short Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
title_sort dual immunotherapy adds value in relapsed/refractory hodgkin lymphoma
topic HemaTopics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745997/
https://www.ncbi.nlm.nih.gov/pubmed/31723786
http://dx.doi.org/10.1097/HS9.0000000000000137
work_keys_str_mv AT hallamsimon dualimmunotherapyaddsvalueinrelapsedrefractoryhodgkinlymphoma